{"entity":{"id":"nct03598257","kind":"trial","name":"Olaparib with or without radiation in inflammatory breast cancer","aka":[],"tldr":"This study tests whether adding olaparib improves radiation treatment for inflammatory breast cancer. It is not accepting new participants.","summary":"Registry status active not recruiting, last updated 2026-09-29. Enrollment is 300 estimated. Non-metastatic inflammatory breast cancer of any receptor subtype after neoadjuvant chemotherapy and modified radical mastectomy with negative margins and axillary evaluation. Randomized radiation with or without olaparib; positive microscopic margins or gross residual tumour after mastectomy are excluded. This disease-specific protocol must not be presented as general postoperative TNBC enrollment.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT03598257","url":"https://clinicaltrials.gov/study/NCT03598257"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03598257","phase":"2","setting":"Non-metastatic inflammatory breast cancer of any receptor subtype after neoadjuvant chemotherapy and modified radical mastectomy with negative margins and axillary evaluation","sponsor":"National Cancer Institute (NCI)","started":"2019-01-18","startedType":"actual","enrolled":300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03598257/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}]}}